More MS news articles for Feb 2002

Angiotech Announces Conference Call and Webcast to Discuss Results of Phase 2 Multiple Sclerosis Study

Feb 22, 2002
Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Feb. 22, 2002-- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI) (TSE:ANP) today announced it has been notified that the Company will soon receive complete data for Angiotech's Phase 2 clinical study for the use of Micellar Paclitaxel (PAXCEED)(TM) for secondary progressive multiple sclerosis. Angiotech will hold an analyst conference call on Monday, February 25, 2002 at 2 PM PST (5 PM EST) to discuss the study results.

Live audio and slideshow presentation of the results will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Access to live and replay audio-visuals of the conference call will be available two hours following the completion of the call at . A recording of the call will also be available until Monday, March 4, 2002 by calling 800/552-5253 and entering Access Code #20376528.

Angiotech Pharmaceuticals, Inc. is a Canadian pharmaceutical company dedicated to the development of medical device coatings and treatments for chronic inflammatory diseases through reformulation of paclitaxel. Several pharmaceutical therapies are in clinical development: systemic Micellar Paclitaxel (PAXCEED)(TM) for secondary progressive multiple sclerosis (Phase 2), rheumatoid arthritis (Phase 1) and severe psoriasis (Pilot Phase 2). The paclitaxel-coated coronary stent program is currently in multiple international clinical studies. Other medical device programs include paclitaxel-loaded surgical implants for the treatment of restenosis associated with peripheral vascular surgery.

Statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes," "may," "will," "estimate," "continue," "anticipates," "intends," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes i n, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.


Angiotech Pharmaceuticals Inc.
Investor Relations:
Rui Avelar, 604/221-7676
Media Relations:
Cindy Yu, 604/221-7676

All Material Subject to Copyright